Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine | Zendy

Katrijn Grupping | Zendy; Laura Cámpora | Zendy; Martine Douha | Zendy; Thomas C. Heineman | Zendy; Nicola P. Klein | Zendy; Himal Lal | Zendy; James T. Peterson | Zendy; Ilse Vastiau | Zendy; Lidia Oostvogels | Zendy

Open Access

Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine

Author(s) -

Katrijn Grupping,

Laura Cámpora,

Martine Douha,

Thomas C. Heineman,

Nicola P. Klein,

Himal Lal,

James T. Peterson,

Ilse Vastiau,

Lidia Oostvogels

Publication year - 2017

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1093/infdis/jix482

Subject(s) - reactogenicity , immunogenicity , vaccination , medicine , immune system , immunology

Protection against herpes zoster (HZ) induced by the live attenuated zoster vaccine Zostavax (ZVL) wanes within 3-7 years. Revaccination may renew protection. We assessed whether (re)vaccination with the adjuvanted HZ subunit vaccine candidate (HZ/su) induced comparable immune responses in previous ZVL recipients and ZVL-naive individuals (HZ-NonVac).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research